Board Change • Jun 01
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Director Milind Pant was the last director to join the board, commencing their role in 2026. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Announcement • May 23
The Joint Corp. Announces Board Changes The Joint Corp. announced the election of Milind Pant to its Board of Directors. Mr. Pant's election follows the Company's annual meeting of stockholders and expands the Board's depth and expertise in international franchising and business expansion. The company thanked Sue Decker and Abe Hong for their many contributions over the past few years, which have been invaluable. The Company extends its sincere gratitude to Sue Decker and Abe Hong whose invaluable contributions over the past few years have greatly benefited the Board. Ms. Decker and Mr. Hong did not stand for re-election at this year’s annual meeting of stockholders. Following the meeting, the Company’s Board consists of seven directors. Mr. Pant is the Founder and Chief Executive Officer of Karyon Leadership Advisory, where he advises senior executives and boards on leadership, transformation, and growth strategy. He also serves on the Board of The Western Union Company and is an Executive Fellow at the Kellogg School of Management and the Wall Street Journal Leadership Institute. Previously, Mr. Pant was CEO of Amway Corporation and held senior executive roles at Yum! Brands, and Unilever PLC, bringing extensive global leadership experience, deep franchising and brand-building expertise, and a strong track record in digital transformation and business turnarounds across international markets. He holds a Master of Business Administration in International Business from the Indian Institute of Foreign Trade and a Master of Management Studies from the Birla Institute of Technology and Science. Reported Earnings • May 11
First quarter 2026 earnings: EPS and revenues exceed analyst expectations First quarter 2026 results: EPS: US$0.078 (up from US$0.033 loss in 1Q 2025). Revenue: US$14.8m (up 13% from 1Q 2025). Net income: US$1.10m (up US$1.61m from 1Q 2025). Profit margin: 7.4% (up from net loss in 1Q 2025). Revenue exceeded analyst estimates by 2.2%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 5.2% p.a. on average during the next 2 years, compared to a 4.7% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. Announcement • Apr 23
The Joint Corp. to Report Q1, 2026 Results on May 07, 2026 The Joint Corp. announced that they will report Q1, 2026 results After-Market on May 07, 2026 Announcement • Apr 14
The Joint Corp. Announces Appointment of Michelle Reap as Director of Franchise Development The Joint Corp. announced Michelle Reap as director of franchise development. Bringing more than 20 years of franchise industry experience, Reap will drive strategic franchise growth with an emphasis on connecting the brand with qualified partners positioned to operate successful, patient-focused clinics as The Joint continues its national expansion. With more than two decades of experience spanning both traditional and nontraditional franchise development, Reap has held leadership roles at some of the most recognized names in the industry, including Yum! Brands and la Madeleine Bakery & Café. She has also served as senior franchise development manager at A&W Restaurants, senior manager of franchise development at The Coffee Bean & Tea Leaf and most recently, director of franchise sales at European Wax Center. Her expertise encompasses new development, growth expansion, resales, renewals, closure mitigation and remodel initiatives. Announcement • Apr 08
The Joint Corp., Annual General Meeting, May 20, 2026 The Joint Corp., Annual General Meeting, May 20, 2026. Reported Earnings • Mar 15
Full year 2025 earnings: EPS and revenues exceed analyst expectations Full year 2025 results: US$0.018 loss per share (improved from US$0.11 loss in FY 2024). Revenue: US$54.9m (up 5.2% from FY 2024). Net loss: US$268.2k (loss narrowed 83% from FY 2024). Revenue exceeded analyst estimates by 2.0%. Earnings per share (EPS) missed analyst estimates. Revenue is forecast to grow 3.2% p.a. on average during the next 2 years, compared to a 4.9% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has fallen by 14% per year whereas the company’s share price has fallen by 19% per year. New Risk • Mar 13
New major risk - Revenue and earnings growth Earnings have declined by 68% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company. Announcement • Mar 13
The Joint Corp. Provides Earnings Guidance for the Year 2026 The Joint Corp. provided earnings guidance for the year 2026. For the year 2026, the company expects system-wide sales are expected to be between $519 million and $552 million, compared to $532.4 million in 2025. Announcement • Feb 26
The Joint Corp. to Report Q4, 2025 Results on Mar 12, 2026 The Joint Corp. announced that they will report Q4, 2025 results After-Market on Mar 12, 2026 Announcement • Jan 06
The Joint Corp. Announces Executive Changes The Joint Corp. appointed Ron Stilwell as Senior Vice President, Operations and Patient Experience, effective immediately January 5, 2026. He fills the role previously held by Eric Wyatt and will report directly to President & CEO Sanjiv Razdan. Throughout his career, Stilwell has successfully leveraged his expertise in franchise operations, P&L management, and customer satisfaction to help franchisors grow and maximize profitability. Prior to joining The Joint®, beginning in 2021 he served as President and Chief Development Officer of FullSpeed Automotive, a prominent automotive aftermarket conglomerate that operates and franchises quick oil change and service centers. He was responsible for the operational excellence and strategic growth initiatives for brands such as Grease Monkey, SpeeDee Oil Change, and Kwik Kar Automotive. FullSpeed Automotive has nearly 1,000 franchised, company and licensed units. From 2018 to 2021, Stilwell was Vice President and Chief Development Officer of Marco’s Pizza, which he helped position as a top franchise brand known for growth and operational excellence. In 2021, Restaurant Business Magazine recognized Marco’s Pizza as the fourth growing franchise. In 2009, he founded Franchise Executive Consultants, a highly successful franchise development and real estate consultancy, which he led through 2018. The firm was the preferred vendor for over 20 large franchise concepts, including Marco’s Pizza, Massage Envy and Verizon Wireless. From 2007 through 2009, he served as SVP and Brand President for Kahala Brands, a diverse portfolio of nationally and internationally acclaimed quick-service restaurant franchise brands. Stilwell holds a Bachelor of Business Administration from Blackstone University and is a Certified Franchise Executive with the International Franchise Association. Reported Earnings • Nov 12
Third quarter 2025 earnings: EPS exceeds analyst expectations Third quarter 2025 results: EPS: US$0.019 (up from US$0.028 loss in 3Q 2024). Revenue: US$13.4m (up 5.7% from 3Q 2024). Net income: US$290.4k (up US$704.8k from 3Q 2024). Profit margin: 2.2% (up from net loss in 3Q 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) exceeded analyst estimates. Revenue is forecast to grow 2.3% p.a. on average during the next 3 years, compared to a 5.5% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 18% per year, which means it has not declined as severely as earnings. Announcement • Nov 07
the Joint Corp. Revises Earnings Guidance for the Full Year 2025 The Joint Corp. revised earnings guidance for the full year 2025. For the period, the company's System-wide sales are now expected to range from $530 million to $534 million, which compares to prior guidance of $530 million to $550 million. Comp sales are now expected to be range from (1)% to 0%, which compares to prior guidance of an increase in the low-single digit range. Announcement • Oct 23
The Joint Corp. to Report Q3, 2025 Results on Nov 06, 2025 The Joint Corp. announced that they will report Q3, 2025 results at 4:00 PM, US Eastern Standard Time on Nov 06, 2025 Announcement • Oct 01
The Joint Corp. Announces Executive Changes The Joint Corp. announced Debbie L. Gonzalez joined as Chief Marketing Officer, effective October 7, 2025, replacing Lori Abou Habib. Debbie L. Gonzalez is a CMO and board director known for building brands, modernizing go-to-market engines, and elevating customer experience with data, analytics, and generative AI. Most recently, she was CMO/SVP, Global Marketing and Communications at Concentrix, a Fortune 500 company, where she led a global team across corporate and employer brand, performance marketing, digital, PR/comms, and creative. Previously, she was Chief Brand/Marketing Officer at Massage Envy Franchising, where she repositioned the business to a Total Body Care wellness platform, centralized performance marketing and digital, lifted brand awareness, and improved reputation ratings. Gonzalez also operated her own consultancy for multi-site consumer services, restaurant, and franchise brands. Early in her career, she held product leadership roles at PetSmart, Herman Millerand Gerber. Gonzalez holds an MBA from Thunderbird and a BBA/Economics from the University of San Diego. She has been featured in CMO.com, CMO Outlook, and AdAge, and volunteers in community leadership roles in Arizona. She currently serves on the board of El Pollo Loco, sitting on the Compensation and Nominating & Governance Committees. Announcement • Aug 13
The Joint Corp. announced delayed 10-Q filing On 08/12/2025, The Joint Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Reported Earnings • Aug 10
Second quarter 2025 earnings: EPS exceeds analyst expectations Second quarter 2025 results: US$0.065 loss per share (improved from US$0.24 loss in 2Q 2024). Revenue: US$13.3m (down 56% from 2Q 2024). Net loss: US$989.6k (loss narrowed 73% from 2Q 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 143%. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has only fallen by 22% per year, which means it has not declined as severely as earnings. Price Target Changed • Aug 08
Price target decreased by 9.2% to US$14.88 Down from US$16.38, the current price target is an average from 4 analysts. New target price is 39% above last closing price of US$10.74. Stock is down 5.0% over the past year. The company is forecast to post a net loss per share of US$0.03 next year compared to a net loss per share of US$0.10 last year. Announcement • Jul 24
The Joint Corp. to Report Q2, 2025 Results on Aug 07, 2025 The Joint Corp. announced that they will report Q2, 2025 results After-Market on Aug 07, 2025 Announcement • Jul 08
Joint Ventures, LLC completed the acquisition of 31 corporate owned and managed clinics in Arizona and New Mexico from The Joint Corp. (NasdaqCM:JYNT) for $8.3 million. Joint Ventures, LLC entered into an Asset Purchase Agreement to acquire 31 corporate owned and managed clinics in Arizona and New Mexico from The Joint Corp. (NasdaqCM:JYNT) for $11.1 million on June 23, 2025. A cash consideration will be paid by Joint Ventures, LLC along with the regional developer (RD) territory rights of the Northwest region. The Transaction is also subject to customary closing conditions. The Purchase Agreement contains other provisions, covenants, representations, and warranties that are typical in transactions of this size, type, and complexity.
The expected completion of the transaction is on June 30, 2025.
Joint Ventures, LLC completed the acquisition of 31 corporate owned and managed clinics in Arizona and New Mexico from The Joint Corp. (NasdaqCM:JYNT) for $8.3 million on July 7, 2025. Announcement • Jun 11
the Joint Corp. Announces CFO Changes, Effective June 10, 2025 The Joint Corp. announced Scott J. Bowman joined as Chief Financial Officer, replacing Jake Singleton, effective June 10, 2025. Scott J. Bowman, age 58, is a seasoned executive and three-time public company CFO with more than 30 years of experience across retail, restaurant, consumer goods, and manufacturing industries. He served as CFO at Leslie’s Inc., a $1.5 billion publicly held pool supply retailer from 2023 to 2025; at True Food Kitchen, a $270 million privately held restaurant company rooted in nutritional science, from 2021 to 2023; at Dave & Buster’s, a $1.4 billion publicly held dining and entertainment company, from 2019 to 2021; and at Hibbett Sports, a $1 billion publicly held athletic specialty retailer that was subsequently acquired by JD Sports, from 2012 to 2019. Prior to that for over two decades, he worked in a series of roles with increasing responsibilities in the finance and accounting departments at The Home Depot, divisions of Newell Rubbermaid, and The Sherwin-Williams Company.Bowman earned a B.S. in Accounting and Finance from Miami University (Ohio) and an MBA from Emory Goizueta Business School. He also holds a CPA designation. Announcement • Jun 04
The Joint Corp. Appoints Sandi Karrmann as Director The Joint Corp. appointed Sandi Karrmann as a Director to help the company strengthen its core, reignite growth and improve profitability. Karrmann increases the board to eight directors. Sandi Karrmann has over two decades of experiences in human resources. Most recently, as Senior Vice President, Chief Human Resources Officer for Kimberly-Clark, she has had global responsibility for the K-C human resources function, including talent recruiting, development/succession, performance management, employee engagement, labor relations, HR operations, compensation, payroll and employee benefits. Prior to this role, Karrmann served as Executive Vice President, Chief Human Resources Officer for Tenet Healthcare and United Surgical Partners International. Prior to USPI, Karrmann served in senior leadership roles at various companies, including Chief People Officer for Yum! Restaurants International, Pizza Hut US and Executive Vice President, CHRO for Meritage Homes Corporation. Prior to Meritage Homes, she served in a number of positions with increasing responsibility over nearly 13 years with PepsiCo, including her last role as Vice President, Human Resources for the sales division of Frito-Lay North America. Karrmann earned a BA degree in Psychology and Communications from the University of Michigan and an MBA in Finance from the University of Southern California. She currently serves as HR Committee Chair and Executive Board member for Camp John Marc, a camp for chronically ill/disabled children, and on the Board of Education is Freedom and United Way of Metropolitan Dallas. Reported Earnings • May 10
First quarter 2025 earnings: EPS exceeds analyst expectations First quarter 2025 results: US$0.033 loss per share (down from US$0.064 profit in 1Q 2024). Revenue: US$13.1m (down 56% from 1Q 2024). Net loss: US$506.0k (down 153% from profit in 1Q 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates. Revenue is forecast to grow 10% p.a. on average during the next 2 years, compared to a 7.0% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 66 percentage points per year, which is a significant difference in performance. Announcement • May 09
The Joint Corp. Reiterates Earnings Guidance for the Full Year 2025 The Joint Corp. reiterated earnings guidance for the full year 2025. For the period, the company's System-wide sales are expected to be between $550 million and $570 million, compared to $530.3 million in 2024. Announcement • May 06
The Joint Corp. Announces Executive Appointments The Joint Corp. welcomed new executives to help execute plans to strengthen the company core, reignite growth, and improve clinic and company-level profitability.Both will report to President and CEO Sanjiv Razdan. Andra J. Terrell, Senior Vice President Legal, undertakes this newly created role to advance legal execution for the franchise system. Eric Wyatt, Senior Vice President Operations and Patient Experience, is tasked to oversee clinic operations, improve quality and economics of the clinics, and elevate the patient experience. Andra J. Terrell: Elevating Legal Structure at The Joint. Terrell most recently served as Senior Assistant General Counsel at Franchise World Headquarters (Subway), where she closed the sale of Subway to Roark Capital, the largest whole business securitization on record and a significant refinancing. Prior, she served as SVP, GC and Corporate Secretary at Regis Corporation, and as VP, Deputy GC and Assistant Secretary at Cajun Operating Company. While Assistant GC at Luxottica Retail North America, Terrell was part of the team that implemented nationwide managed vision care agreement as well as new Pearle Vision Full Service Program. Other legal roles were at GNC Franchising and Decorating Den Systems. Terrell holds a Bachelor of Science in Natural Sciences and History of Science from John Hopkins University and a Juris Doctor from Howard University School of Law. A prolific author, Terrell has published multiple legal handbooks, papers and articles. Eric Wyatt: Bringing Franchise Operations Expertise for Nationally Recognized Brands. Wyatt most recently served as CEO of Clean Eatz LLC, overseeing a franchise organization with over 100 locations in 23 states and multiple revenue streams. Prior, he was President & CEO of Norms Restaurant LLC, a Southern California-based diner chain with more than $150 million in annual revenue. Wyatt also held senior leadership roles at CKE Restaurants as SVP of Operations for the Hardee’s brand, and CEO and COO at Boston Market Corporation, where he led transformational change and operational excellence initiatives across hundreds of locations. Wyatt’s earlier experience includes executive roles at Panera Bread, L Brands, and Starbucks Corporation. He began his career in franchise and company operations at Taco Bell and Mobil Oil. Wyatt holds a Bachelor of Arts in Speech Communications from East Stroudsburg University and serves on the Board of Directors for the East Stroudsburg University Foundation. Announcement • Apr 24
The Joint Corp. to Report Q1, 2025 Results on May 08, 2025 The Joint Corp. announced that they will report Q1, 2025 results After-Market on May 08, 2025 Announcement • Apr 10
The Joint Corp., Annual General Meeting, May 21, 2025 The Joint Corp., Annual General Meeting, May 21, 2025. Location: 16767 n. perimeter drive, suite 110, arizona 85260, scottsdale United States Reported Earnings • Mar 14
Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2024 results: US$0.10 loss per share (improved from US$0.66 loss in FY 2023). Revenue: US$51.9m (down 56% from FY 2023). Net loss: US$1.54m (loss narrowed 84% from FY 2023). Revenue exceeded analyst estimates by 2.5%. Earnings per share (EPS) missed analyst estimates by 52%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 70 percentage points per year, which is a significant difference in performance. Announcement • Mar 14
The Joint Corp. Provides Earnings Guidance for the Full Year 2025 The Joint Corp. provided earnings guidance for the full year 2025. For the period, the company's System-wide sales are expected to be between $550 million and $570 million, compared to $530.3 million in 2024. Announcement • Mar 11
The Joint Corp. Appoints Craig Sherwood as Senior Vice President of Development The Joint Corp. announced the appointment of Craig Sherwood as the company’s new Senior Vice President of Development. He will report to President and CEO Sanjiv Razdan. Sherwood will be responsible for leading franchise license sales and new clinic development as well as building out the company’s enterprise accounts business. Announcement • Jan 16
The Joint Corp. to Report Q4, 2024 Results on Mar 13, 2025 The Joint Corp. announced that they will report Q4, 2024 results After-Market on Mar 13, 2025 Announcement • Nov 09
The Joint Corp. Adjusts System-Wide Sales Guidance for 2024 The Joint Corp. adjusted all elements of its guidance for 2024. System-wide sales are expected to be between $525 million and $535 million compared to $488 million in 2023. Reported Earnings • Nov 08
Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Third quarter 2024 results: US$0.21 loss per share (further deteriorated from US$0.048 loss in 3Q 2023). Revenue: US$30.2m (up 2.5% from 3Q 2023). Net loss: US$3.17m (loss widened 342% from 3Q 2023). Revenue exceeded analyst estimates by 6.4%. Earnings per share (EPS) missed analyst estimates. Revenue is expected to decline by 14% p.a. on average during the next 3 years, while revenues in the Healthcare industry in the US are expected to grow by 6.6%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 75 percentage points per year, which is a significant difference in performance. Announcement • Nov 08
The Joint Corp. Updates Earnings Guidance for the Year 2024 The Joint Corp. updated earnings guidance for the year 2024. For the period, the company's System-wide sales are expected to be between $525 million and $535 million, adjusted from $530 million and $545 million and compared to $488.0 million in 2023. Announcement • Oct 24
The Joint Corp. to Report Q3, 2024 Results on Nov 07, 2024 The Joint Corp. announced that they will report Q3, 2024 results After-Market on Nov 07, 2024 Buy Or Sell Opportunity • Aug 11
Now 23% undervalued after recent price drop Over the last 90 days, the stock has fallen 31% to US$11.30. The fair value is estimated to be US$14.69, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Meanwhile, the company became loss making. Reported Earnings • Aug 09
Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Second quarter 2024 results: US$0.24 loss per share (further deteriorated from US$0.022 loss in 2Q 2023). Revenue: US$30.3m (up 3.3% from 2Q 2023). Net loss: US$3.60m (loss widened US$3.28m from 2Q 2023). Revenue exceeded analyst estimates by 2.9%. Earnings per share (EPS) missed analyst estimates. Revenue is expected to decline by 14% p.a. on average during the next 3 years, while revenues in the Healthcare industry in the US are expected to grow by 6.8%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 72 percentage points per year, which is a significant difference in performance. Announcement • Jul 25
The Joint Corp. to Report Q2, 2024 Results on Aug 08, 2024 The Joint Corp. announced that they will report Q2, 2024 results at 4:00 PM, US Eastern Standard Time on Aug 08, 2024 New Risk • May 07
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (2.8% increase in shares outstanding). Price Target Changed • May 05
Price target increased by 9.7% to US$13.38 Up from US$12.19, the current price target is an average from 4 analysts. New target price is 17% below last closing price of US$16.12. Stock is up 6.7% over the past year. The company is forecast to post earnings per share of US$0.054 next year compared to a net loss per share of US$0.66 last year. Reported Earnings • May 04
First quarter 2024 earnings: EPS exceeds analyst expectations First quarter 2024 results: EPS: US$0.064 (down from US$0.16 in 1Q 2023). Revenue: US$29.7m (up 5.0% from 1Q 2023). Net income: US$947.0k (down 59% from 1Q 2023). Profit margin: 3.2% (down from 8.2% in 1Q 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) exceeded analyst estimates. Revenue is expected to decline by 11% p.a. on average during the next 2 years, while revenues in the Healthcare industry in the US are expected to grow by 6.7%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 79 percentage points per year, which is a significant difference in performance. Announcement • May 03
The Joint Corp. Reiterates Sales Guidance for the Year 2024 The Joint Corp. reiterated sales guidance for the year 2024. 2024 System-wide sales are expected to be between $530 million and $545 million, compared to $488.0 million in 2023. System-wide comp sales for all clinics open 13 months or more are expected to be in the mid-single digits in 2024. Announcement • Apr 21
The Joint Corp., Annual General Meeting, May 22, 2024 The Joint Corp., Annual General Meeting, May 22, 2024, at 09:00 US Mountain Standard Time. Location: 16767 N. Perimeter Drive, Suite 110 Scottsdale Arizona United States Agenda: To elect seven directors; to approve the compensation of the executive officers; to ratify the appointment of BDO USA, P.C. as its independent registered public accounting firm for 2024; and to approve the Joint Corp. 2024 Incentive Stock Plan. Announcement • Apr 20
The Joint Corp. to Report Q1, 2024 Results on May 02, 2024 The Joint Corp. announced that they will report Q1, 2024 results After-Market on May 02, 2024 New Risk • Mar 09
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Reported Earnings • Mar 08
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2023 results: US$0.66 loss per share (down from US$0.043 profit in FY 2022). Revenue: US$117.7m (up 16% from FY 2022). Net loss: US$9.75m (down US$10.4m from profit in FY 2022). Revenue exceeded analyst estimates by 1.3%. Earnings per share (EPS) missed analyst estimates. Revenue is expected to decline by 8.9% p.a. on average during the next 2 years, while revenues in the Healthcare industry in the US are expected to grow by 6.7%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 58 percentage points per year, which is a significant difference in performance. Announcement • Mar 08
The Joint Corp. Provides Sales Guidance for the Year 2024 The Joint Corp. provided sales guidance for the year 2024. 2024 System-wide sales are expected to be between $530 and $545 million dollars, compared to $488.0 million in 2023. System-wide comp sales for all clinics open 13 months or more are expected to be in the mid-single digits in 2024. Valuation Update With 7 Day Price Move • Feb 12
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to US$10.95, the stock trades at a forward P/E ratio of 66x. Average forward P/E is 12x in the Healthcare industry in the US. Total loss to shareholders of 71% over the past three years. Announcement • Jan 12
The Joint Corp. to Report Second Half, 2023 Results on Mar 07, 2024 The Joint Corp. announced that they will report second half, 2023 results on Mar 07, 2024 Major Estimate Revision • Nov 20
Consensus EPS estimates fall by 42% The consensus outlook for fiscal year 2023 has been updated. 2023 EPS estimate fell from US$0.168 to US$0.098. Revenue forecast unchanged from US$116.0m at last update. Net income forecast to shrink 1.6% next year vs 18% growth forecast for Healthcare industry in the US . Consensus price target of US$15.63 unchanged from last update. Share price rose 2.2% to US$8.48 over the past week. Reported Earnings • Nov 15
Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Third quarter 2023 results: US$0.048 loss per share (down from US$0.034 profit in 3Q 2022). Revenue: US$29.5m (up 11% from 3Q 2022). Net loss: US$716.3k (down 246% from profit in 3Q 2022). Revenue exceeded analyst estimates by 2.2%. Earnings per share (EPS) missed analyst estimates. Revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 6.9% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has fallen by 62% per year but the company’s share price has only fallen by 30% per year, which means it has not declined as severely as earnings. Board Change • Nov 15
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 1 highly experienced director. Independent Director Glenn Krevlin was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Nov 11
The Joint Corp. Reiterates Revenue Guidance for the Year 2023 The Joint Corp. reiterated revenue guidance for the year 2023. For 2023, Revenue is expected to be between $115.0 million and $118.0 million, compared to $101.9 million in 2022. Announcement • Nov 09
The Joint Corp. Appoints Jeff Gramm to the Board of Directors, Effective January 2, 2024 The Joint Corp. will appoint Jeff Gramm to the board of directors, effective January 2, 2024 and nominate him for election to the board at the company's 2024 Annual Meeting of shareholders. Gramm fills a vacated seat, and the current board size remains at seven. Jeff Gramm:-Jeff Gramm is a portfolio manager of Bandera Partners, a value-oriented investment partnership that he co-founded in 2006. He has served on several public company boards of directors, including Tandy Leather Factory, Rubicon Technology, Innovative Food Holdings, Ambassadors Group, Morgan's Foods, and Peerless Systems. Gramm earned his MBA at Columbia Business School and his BA at University of Chicago. Announcement • Oct 27
The Joint Corp. to Report Q3, 2023 Results on Nov 09, 2023 The Joint Corp. announced that they will report Q3, 2023 results After-Market on Nov 09, 2023 Announcement • Sep 14
The Joint Corp. Revises Earnings Guidance for the Year 2023 The Joint Corp. revised earnings guidance for the year 2023. For the period, the company expects revenue to be between $115.0 million and $118.0 million, compared to $101.9 million in 2022. Previous revenue guidance was between $123.0 million and $128.0 million. Announcement • Aug 26
The Joint Announces Receipt of Delinquency Notification Letter from Nasdaq The Joint Corp. announced that it received a delinquency notification letter from the Listing Qualifications Staff (the ‘Staff’) of the Nasdaq Stock Market LLC (‘Nasdaq’) on August 22, 2023 due to the Company’s non-compliance with Nasdaq Listing Rule 5250(c)(1) (the ‘Listing Rule’) as a result of the Company’s failure to timely file its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2023 (the ‘Form 10-Q’). The Listing Rule requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the ‘SEC’). The Company timely filed a Form 12b-25 Notification of Late Filing related to the Form 10-Q, which resulted in an extended filing deadline for the Form 10-Q of August 21, 2023. The Form 10-Q was not filed with the SEC on August 21, 2023, as the Company continues the evaluation of its accounting treatment related to the Company’s regional developer arrangements and the related impact to its current and previously issued financial statements, which is necessary for the Company’s independent registered accounting firm to complete its quarterly review procedures related to Form 10-Q. Nasdaq has informed the Company that the Company must submit a plan of compliance (the ‘Plan’) by October 23, 2023 addressing how it intends to regain compliance with Nasdaq’s listing rules. The Company will continue to work with its auditors with the objective of filing its Form 10-Q as soon as practicable and will work diligently to submit the Plan promptly and take the necessary steps to regain compliance as soon as practicable. Announcement • Aug 17
The Joint Corp. announced delayed 10-Q filing On 08/15/2023, The Joint Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Announcement • Aug 15
The Joint Corp. Appoints Lori Abou Habib as New Chief Marketing Officer The Joint Corp. announced the hiring of Lori Abou Habib, as its new Chief Marketing Officer. Reporting directly to Peter D. Holt, President and Chief Executive Officer of The Joint Corp., Abou Habib is tasked with leading marketing and strategic planning to advance enterprise initiatives and grow performance of clinics, franchise prospects and consumer awareness. Prior to The Joint, Abou Habib served for six years as senior vice president and chief marketing officer of SONIC America's Drive-In, part of the Inspire Brands family of restaurants. In her role, she led all marketing strategy for SONIC, which included national marketing, media, digital strategy, marketing technology and product innovation. A 15-year veteran of SONIC, Abou Habib earned several promotions with increasing responsibility. Previous to SONIC, she worked at CKE Restaurants Inc. and Eateries Inc. Abou Habib obtained her Bachelor of Business Administration from the University of Central Oklahoma. She also received her Master of Business Administration from Webster International University in London. Price Target Changed • Aug 11
Price target decreased by 8.5% to US$27.17 Down from US$29.70, the current price target is an average from 3 analysts. New target price is 170% above last closing price of US$10.06. Stock is down 55% over the past year. The company is forecast to post earnings per share of US$0.26 for next year compared to US$0.081 last year. Announcement • Jul 14
The Joint Corp. to Report Q2, 2023 Results on Aug 10, 2023 The Joint Corp. announced that they will report Q2, 2023 results After-Market on Aug 10, 2023 Announcement • May 06
The Joint Corp. Provides Earnings Guidance for the Year 2023 The Joint Corp. provided earnings guidance for the year 2023. Revenue is expected to be between $123.0 million and $128.0 million, compared to $101.9 million in 2022. Reported Earnings • May 06
First quarter 2023 earnings: EPS and revenues exceed analyst expectations First quarter 2023 results: EPS: US$0.16 (up from US$0.014 loss in 1Q 2022). Revenue: US$28.5m (up 27% from 1Q 2022). Net income: US$2.30m (up US$2.51m from 1Q 2022). Profit margin: 8.1% (up from net loss in 1Q 2022). The move to profitability was driven by higher revenue. Revenue exceeded analyst estimates by 1.6%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 7.4% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings. Price Target Changed • Apr 08
Price target increased by 11% to US$29.70 Up from US$26.75, the current price target is an average from 5 analysts. New target price is 86% above last closing price of US$15.93. Stock is down 53% over the past year. The company is forecast to post earnings per share of US$0.10 for next year compared to US$0.081 last year. Major Estimate Revision • Mar 17
Consensus EPS estimates fall by 44%, revenue upgraded The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast increased from US$121.4m to US$122.7m. EPS estimate fell from US$0.195 to US$0.108 per share. Net income forecast to grow 39% next year vs 10% growth forecast for Healthcare industry in the US. Consensus price target broadly unchanged at US$27.25. Share price fell 2.5% to US$16.09 over the past week. Reported Earnings • Mar 10
Full year 2022 earnings: EPS misses analyst expectations Full year 2022 results: EPS: US$0.081 (down from US$0.46 in FY 2021). Revenue: US$101.9m (up 26% from FY 2021). Net income: US$1.18m (down 82% from FY 2021). Profit margin: 1.2% (down from 8.1% in FY 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 32%. Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 7.7% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings. 